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Abstract: Most cases of hemorrhagic fever with renal syndrome (HFRS) in Europe are caused by
the Puumala hantavirus (PUUV). Typical features of the disease are increased vascular permeability,
acute kidney injury (AKI), and thrombocytopenia. YKL-40 is an inflammatory glycoprotein involved
in various forms of acute and chronic inflammation. In the present study, we examined plasma
YKL-40 levels and the associations of YKL-40 with disease severity in acute PUUV infection. A total
of 79 patients treated in Tampere University Hospital during 2005–2014 were studied. Plasma YKL-40
was measured in the acute phase, the recovery phase, and one year after hospitalization. Plasma
YKL-40 levels were higher during the acute phase compared to the recovery phase and one year after
hospitalization (median YKL-40 142 ng/mL, range 11–3320, vs. 45 ng/mL, range 15–529, vs. 32 ng/mL,
range 3–213, p < 0.001). YKL-40 level was correlated with the length of hospital stay (r = 0.229,
p = 0.042), the levels of inflammatory markers—that is, blood leukocytes (r = 0.234, p = 0.040), plasma
C-reactive protein (r = 0.332, p = 0.003), and interleukin-6 (r = 0.544, p < 0.001), and maximum plasma
creatinine level (r = 0.370, p = 0.001). In conclusion, plasma YKL-40 levels were found to be elevated
during acute PUUV infection and correlated with the overall severity of the disease, as well as with
the degree of inflammation and the severity of AKI.
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1. Introduction
Hantaviruses have caused hemorrhagic fever with renal syndrome (HFRS) in Europe and Asia,
and hantavirus cardiopulmonary syndrome (HCPS) in America [1–3]. The Hantaan virus (HTNV)
and Seoul virus (SEOV) have caused HFRS in Asia, whereas the Puumala virus (PUUV) and Dobrava
virus (DOBV) are prevalent in Europe [1–3]. Most of the European HFRS cases are caused by PUUV.
A majority of these infections have been reported in Finland, with thousands of serologically diagnosed
cases each year [4].
The typical features of PUUV infection are increased vascular permeability, acute kidney
injury (AKI), and thrombocytopenia, with the last one rarely causing serious hemorrhages [5–9].
The patients typically suffer from high fever, headache, abdominal and back pain, nausea, and visual
disturbances [5–9]. Renal involvement in PUUV infection causes transient proteinuria, hematuria,
temporarily decreased glomerular filtration, and oliguria, followed by polyuria and spontaneous
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recovery [5,7,8,10]. The severity of PUUV infection varies remarkably from subclinical disease to
rare fatal cases, with the mortality ranging from less than 0.1% in Finland to 0.4% in Sweden [11,12].
Nevertheless, the disease often leads to hospitalization, and sometimes to intensive care unit treatment,
including renal replacement therapy (RRT) [8]. Factors affecting the severity of PUUV infection have
not yet been fully revealed. Host genetics, however, are known to influence the outcome [13–15].
Furthermore, smokers have a more severe AKI than non-smokers [10,16,17]. Nevertheless, the outcome
of AKI in PUUV infection is favorable [10,18].
A central phenomenon in hantavirus infections is increased capillary permeability, leading to
vascular leakage [3,8]. The exact pathogenetic mechanisms underlying this phenomenon are unclear.
The endothelium of the small vessels in various organs is the primary target of hantavirus infection,
but widespread cytopathic effects on the endothelial cells have not been found [3,8]. Therefore,
immunological or inflammatory host mechanisms are most probably important in the pathogenesis of
the capillary injury [3,8].
Complement activation, as well as several biomarkers, including plasma interleukin (IL)-6,
indoleamine 2,3-dioxygenase, pentraxin-3, soluble urokinase-type plasminogen activator receptor
(suPAR), and cell-free DNA have been shown to predict the outcome of PUUV infection [19–24].
Furthermore, urinary IL-6, GATA-3, and neutrophil gelatinase-associated lipocalin (NGAL) have been
found to be associated with the severity of AKI [22,25,26]. The amount of albuminuria and hematuria,
as well as glucosuria in the acute phase predict the severity of AKI in PUUV-infected patients [27–29].
On the contrary, although plasma C-reactive protein (CRP) is elevated in almost all patients with
PUUV infection, a high CRP level does not indicate a more severe disease [21]. Recently, we studied
the adipokines adiponectin, leptin, and resistin in PUUV infection and found plasma resistin to be an
independent risk factor for the severity of AKI [30].
YKL-40, also known as chitinase 3-like protein 1 (CHI3L1), is an inflammatory glycoprotein
secreted by a variety of cells, particularly by activated macrophages and neutrophils, in different
tissues with inflammation [31,32]. It is also produced by vascular smooth muscle cells in response to
endothelial damage [32]. YKL-40 acts as an inflammatory factor in various forms of acute and chronic
inflammation, and is involved in the pathogenesis of several diseases [31,32].
In this study, we examined the associations of YKL-40, a multifunctional inflammatory factor,
with inflammation, AKI, and the overall disease severity in HFRS induced by PUUV.
2. Materials and Methods
2.1. Subjects
The study cohort originally consisted of 86 consecutive patients with acute, serologically confirmed
PUUV infection treated in Tampere University Hospital in Finland during January 2005 to November
2014. Plasma samples for YKL-40 measurements were available from 79 patients, and these patients
comprised the final study cohort. A detailed medical history was obtained and careful physical
examination was performed during the acute phase of the disease. All patients provided a written
informed consent, and the study was approved by the Ethics Committee of Tampere University
Hospital (R04180 date 07.12.2004, R09206 date 10.12.2009).
The median age of the patients was 41 (range 21–74) years, and 48 patients (61%) were males.
Of the patients, 24 (30%) had one or more of the following diseases diagnosed before acute PUUV
infection: hypertension (n = 7), asthma/chronic obstructive pulmonary disease (n = 4), gastritis/reflux
disease (n = 4), rheumatoid arthritis (n = 3), coronary artery disease (n = 2), type 2 diabetes (n = 2),
type 1 diabetes (n = 1), and transient ischemic attack (n = 1). Some of the patients had more than one
disease, but none had a known kidney disease or chronic renal insufficiency.
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2.2. Laboratory Measurements
The acute PUUV infection was confirmed from a single serum sample by detecting the
typical granular staining pattern in immunofluorescence assay (IFA) [33], and/or low avidity of
immunoglobulin (Ig)G antibodies to PUUV [34], and/or by detecting PUUV IgM antibodies by an
“in-house” enzyme-linked immunosorbent assay (ELISA), based on recombinant antigens [35].
Plasma creatinine was measured daily during hospitalization, with a median of five (2–13)
measurements per patient, by a Cobas Integra analyzer (F. Hoffman- La Roche Ltd., Basel, Switzerland).
A urine dipstick test was performed on admission to hospital. The urine dipstick analyses were
performed by automated tests based on refractometry (Siemens Clinitec Atlas or Advantus). The dipstick
assay detects albumin, and it does not react with immunoglobulins, immunoglobulin light chains,
or tubular proteins. The sensitivity of the assay to urine albumin is 0.15–0.3 g/L (U-Alb 1+), ≥1 g/L
(U-Alb 2+), and ≥3 g/L (U-Alb 3+). The assay for hematuria detects heme pseudoperoxidase activity,
and therefore, it detects red cell casts and dysmorphic red cells as well. The sensitivity of the assay
is about 10 × 106 cells/L (about 3–5 cells by high power field). The dipstick test for glucose detects
glucosuria from glucose level 3–5 mmol/L upwards. Glucosuria 3+ corresponds to a urine glucose
level higher than 30 mmol/L.
Plasma samples for the measurement of YKL-40, resistin, leptin, and adiponectin concentrations, as
well as CRP and IL-6 levels were collected between 7:30–8:30 am, with a median of two (1–5) times during
hospitalization. The follow-up samples were obtained at a median of 15 (range 7–21) days after discharge
from hospital in 74 patients, and one year after hospitalization in 67 patients. Plasma YKL-40, resistin,
leptin, adiponectin, CRP, and IL-6 concentrations were measured by an enzyme-linked immunosorbent
assay (ELISA) using reagents from R&D Systems Europe Ltd., Abingdon, UK (YKL-40, resistin, leptin,
adiponectin, and CRP) and from eBioscience Inc, San Diego, CA, USA (IL-6). The detection limit and
interassay coefficient of variation were 15.6 pg/mL and 4.2% for YKL-40, 15.6 pg/mL and 8.5% for
resistin, 15.6 pg/mL and 5.3% for leptin, 15.6 pg/mL and 6.0% for adiponectin, 3.9 pg/mL and 5.7% for
CRP, and 0.39 pg/mL and 4.8% for IL-6. For adiponectin, the test detects total adiponectin.
Blood cell counts were determined by hematological cell counters (Bayer Diagnostics, Elkhart, IN,
USA). Other analytical procedures were carried out with an automated chemistry analyzer using the
routine procedure. The highest or lowest values (as appropriate) of the various variables measured
during the hospital stay were designated as the maximum or minimum values. All routine laboratory
analyses were performed by the Laboratory Centre of Pirkanmaa Hospital District (later named Fimlab
Laboratories), Tampere, Finland.
Here, shock is defined by a fall in systolic blood pressure under 90 mmHg, together with the
clinical symptoms of shock. Body mass index (BMI) was calculated as the ratio of weight (kg) to
squared height (m2).
2.3. Statistical Analyses
Medians and ranges are given for continuous variables, and numbers and percentages for
categorical variables. Spearman’s rank correlations were calculated. Categorical data were analyzed
using the x2 test or the Fisher’s exact test, and groups were compared using the Mann-Whitney U-test
or the Kruskal-Wallis test, as appropriate. Related samples were compared using the Wilcoxon signed
rank test or the Friedman test, as appropriate. All tests were two-sided, and the p-values are given.
The analyses were performed using SPSS (version 20) statistical software (IBM, Chicago, IL, USA).
3. Results
The clinical characteristics and laboratory findings of the patients are shown in Table 1. The patients
were admitted to the hospital at a median of four (range 1–8) days after the onset of fever. The median
duration of the hospital stay was six (range 2–14) days. Two patients (3%) presented with clinical shock on
admission, and one patient (1%) needed RRT during hospitalization. All the patients recovered completely.
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Table 1. Clinical and laboratory findings in 79 patients with Puumala hantavirus infection.
Findings Median Range
Age (years) 41 21–74
Body mass index (kg/m2) 26 19–37
Duration of fever (days) 8 4–15
Length of hospital stay (days) 6 2–14
Systolic blood pressure min (mmHg) 113 74–170
Change in body weight (kg) 2 0–11
Creatinine max (µmol/L) 186 51–1499
Sodium min (mmol/L) 130 109–139
Potassium max (mmol/L) 4.2 3.3–5.3
Albumin min (g/L) n = 32 25 18–34
Hematocrit max 0.44 0.33–0.60
Hematocrit min 0.36 0.25–0.44
Platelets min (×109/L) 52 5–150
Leukocytes, max (×109/L) 10,8 4.2–45
CRP max (mg/L) 57 8–199
IL-6 max (ρg/mL) 11.8 1.6–66.6
YKL-40 max (ng/mL) 142 11–3320
Resistin max (ng/mL) 28 11–107
Leptin min (ng/mL) 5.3 1.2–48.4
Adiponectin min (µg/mL) 3.76 0.23–10.66
Adiponectin max (µg/mL) 4.08 0.62–10.77
min, minimum value during hospital stay; max, maximum value during hospital stay; CRP, C-reactive protein;
IL-6, interleukin-6.
Plasma YKL-40 was elevated during the acute phase, compared to the values in the recovery
phase and one year after the infection. Figure 1A shows the trend of YKL-40 levels over time during
the acute phase. The YKL-40 level remained elevated during the entire acute phase without any clear
peak. The median of maximum levels of YKL-40 during hospitalization was 142 ng/mL (range 11-3320).
Fifteen days and one year after the hospitalization, the median YKL-40 levels were 45 ng/mL (range
15–529) and 32 ng/mL (range 3–213), respectively (p < 0.001 for both compared to the acute phase)
(Figure 1B). The maximum plasma YKL-40 level did not differ between the sexes (168 ng/mL, range
12–3321 vs. 134 ng/mL, range 26–2223, male vs. female, p = 0.188).
Figure 1. Cont.
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Figure 1. (A) The trend of YKL-40 levels during the acute phase in relation to the onset of fever. (B)
YKL-40 levels during hospitalization (maximum), fifteen days and one year after the hospitalization.
Outliers have been omitted from the figure.
Table 2 shows the correlations of maximum plasma YKL-40 level with clinical and laboratory
variables. YKL-40 level correlated positively with inflammatory markers—that is, blood leukocyte
count, plasma CRP, and, particularly, with plasma IL-6 levels. A positive correlation was also seen
with the highest plasma creatinine level and the duration of hospital stay, the latter one reflecting
the overall severity of the disease. There was no correlation between YKL-40 and the maximum
hematocrit level, the minimum albumin level, or the change in body weight—that is, the signs of
vascular leakage. Furthermore, no correlation with thrombocytopenia was seen. YKL-40 was correlated
with age. The plasma YKL-40 level was correlated with the plasma resistin level (r = 0.320, p = 0.004),
but not with the levels of the two other adipokines, adiponectin and leptin (r = −0.180, p = 0.112 for
minimum adiponectin; r = −0.097, p = 0.395 for minimum leptin level).




Body mass index 0.016 0.892
Length of hospital stay 0.229 0.042
Systolic blood pressure min −0.032 0.777
Change in body weight * 0.105 0.370
Creatinine max 0.370 0.001
Potassium max 0.236 0.036
Sodium min −0.286 0.011
Albumin min 0.093 0.644
Hematocrit max 0.201 0.076
Hematocrit min −0.262 0.020
Platelets min −0.020 0.858
Leukocytes max 0.234 0.040
CRP max 0.332 0.003
IL-6 max 0.544 <0.001
min, minimum value during hospital stay; max, maximum value during hospital stay; CRP, C-reactive protein; IL-6,
interleukin-6; * reflects fluid retention during the oliguric phase.
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We then divided the patients into two groups according to the maximum plasma YKL-40 level:
YKL-40 ≤ 142 ng/mL and YKL-40 > 142 ng/mL (142 ng/mL was the median in the study population).
The patients with higher YKL-40 levels had a more severe AKI and higher levels of the inflammatory
markers (blood leukocyte count, and plasma CRP and IL-6), compared to the patients with lower
YKL-40 concentrations (Table 3). The patients with higher YKL-40 levels were older than the patients
with lower YKL-40 levels.
Table 3. Comparisons of clinical and laboratory findings in 79 patients with Puumala hantavirus
infection divided into two groups according to YKL-40 level.
YKL-40 ≤ Median YKL-40 > Median p
Age (years) 35 (21–67) 48 (25–74) 0.001
Body mass index (kg/m2) 25 (20–37) 27 (19–37) 0.474
Length of hospital stay (days) 6 (2–9) 7 (2–14) 0.102
Change in body weight (kg) * 1.7 (0–11.3) 2.2 (0–10.8) 0.329
Urinary output min (mL/day) 1200 (100–5720) 1160 (200–3190) 0.666
Creatinine max (µmol/L) 103 (51–1071) 263 (71–1499) 0.005
Potassium max (mmol/L) 4.2 (3.3–5.2) 4.3 (3.5–5.3) 0.316
Sodium min (mmol/L) 131 (118–139) 129 (109–139) 0.038
Albumin min (g/L) 24 (18–33) 25 (20–34) 0.375
Hematocrit max 0.44 (0.36–0.60) 0.47 (0.33–0.59) 0.053
Hematocrit min 0.36 (0.28–0.42) 0.35 (0.25–0.44) 0.216
Platelets min (×109/L) 44 (23–112) 61 (5–150) 0.182
Leukocytes max (×109/L) 10.0 (6.4–18.7) 12.2 (4.2–45.0) 0.051
CRP max (mg/L) 45 (8–130) 65 (15–199) 0.033
IL-6 max (ρg/mL) 8.4 (1.7–42.2) 17.1 (2.0–66.6) 0.001
min, minimum; max, maximum; CRP, C-reactive protein; IL-6, interleukin-6; * reflects fluid retention during the
oliguric phase.
There was no difference in plasma YKL-40 level between patients with no proteinuria or proteinuria
level 1+, 2+, or 3+ (YKL-40 median 75, range 26–1296, ng/mL vs 128, range 36–1836, ng/mL vs 178,
range 32–2223, ng/mL vs 166, range 12–3321, ng/mL, p = 0.301), or between patients with no hematuria
or hematuria level 1+, 2+, or 3+ (YKL-40 median 112, range 36–374, ng/mL vs 136, range 26–1296,
ng/mL vs 190, range 24–3321, ng/mL vs 177, range 12–1247, ng/mL, p = 0.381), or between patients
with and without glucosuria (YKL-40 median 102, range 12–1853, ng/mL vs 164, range 26–3321, ng/mL,
p = 0.293).
4. Discussion
The present study shows that plasma YKL-40 levels are elevated during acute hantavirus infection
caused by PUUV. The concentrations measured during the acute illness were markedly higher than
the values measured after hospitalization, which, in turn, corresponded to the YKL-40 levels of local
healthy subjects in our previous studies [36,37]. To our knowledge, no previous studies have been
published on YKL-40 in a hantavirus infection.
YKL-40 or CHI3L1 is a heparin- and chitin-binding glycoprotein with a molecular weight of 40 kDa,
and is secreted by a variety of cells, particularly activated macrophages, neutrophils, and vascular
smooth muscle cells on sites of inflammation [31,32]. It is involved in the activation of the innate
immune system and maturation of monocytes to macrophages [32]. YKL-40 is involved in endothelial
dysfunction by promoting chemotaxis, cell attachment and migration, reorganization, and tissue
remodeling in response to endothelial damage [32]. It acts as an inflammatory factor in both acute and
chronic inflammation and is involved in the pathogenesis of atherosclerosis, cardiovascular disease,
diabetes, and cancer [31,32]. However, the complete biological function and specific receptor(s) of
YKL-40 still remain unknown [31]. We have previously found YKL-40 as a contributing factor and
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biomarker in asthma, osteoarthritis, rheumatoid arthritis, and asbestosis, as well as a predictive factor
in renal cell cancer [36,38–41].
Previously, YKL-40 levels have been reported to predict the outcome of some bacterial infections.
YKL-40 level was found to be connected with the severity of community acquired pneumonia and the
outcome of pneumococcal bacteremia, as well as survival in sepsis [42–44]. Furthermore, in cellulitis
and pelvic inflammatory disease, YKL-40 has predicted the clinical course [45,46]. In scrub typhus,
YKL-40 associates with disease severity and mortality [47]. In viral infections, however, previous studies
concerning YKL-40 are scarce but support the present findings. Serum YKL-40 serves as a marker of
fibrosis after liver transplantation for hepatitis C and hepatitis B [48,49]. Furthermore, in hepatitis C,
the YKL-40 level decreases in response to antiviral treatment [50]. In HIV infection, cerebrospinal
fluid YKL-40 has been found to be elevated in chronic HIV infection, as well as in HIV-associated
dementia [51,52]. In RSV infection, elevated YKL-40 levels were found in nasopharyngeal aspirates,
and studies on mice suggest that YKL-40 may contribute to airway inflammation in RSV infection [53].
In the present study, plasma YKL-40 level was associated with the length of hospital stay, which
reflects the overall severity of acute PUUV infection. In addition, the present study shows that in
PUUV infection, YKL-40 predicts the severity of the disease, in terms of inflammation and AKI.
Furthermore, plasma YKL-40 levels remain elevated during the acute phase of PUUV infection as a
sign of undergoing inflammation.
The maximum plasma YKL-40 level was correlated with the inflammatory markers—that is,
blood leukocyte count and plasma CRP and IL-6 levels. This is in accordance with the perception of
YKL-40 as an early inflammatory marker. This finding is also in concordance with previous studies,
reporting a positive correlation of YKL-40 with IL-6 or CRP in some other inflammatory or infectious
conditions [31,32,36,39,46]. In PUUV infection, on the other hand, IL-6 has predicted the outcome,
but the predictive value of CRP is less clear [21]. This is of interest, as YKL-40 correlated more strongly
with IL-6 than CRP in the present study. In addition, we found that plasma YKL-40 correlated positively
with the level of resistin. YKL-40 levels have previously been found to correlate with resistin levels in
marathon runners [37]. In addition, high resistin concentrations have been shown to predict severe
AKI in PUUV infection [30].
Increased capillary permeability is a central feature in hantavirus infections [3,8], but the
pathogenesis of the vascular leakage has not been clarified in detail. Inflammatory or immunological
factors are most probably important, since no direct cytopathic effects are seen on the vascular
endothelium [3,8]. In general, YKL-40 is involved in the development of endothelial dysfunction,
and it has been suggested to have a role in the development of atherosclerosis [32]. In the present
study, however, there was no correlation of YKL-40 level with the signs of vascular leakage—that is,
the change in body weight, the highest hematocrit, or the lowest albumin level. Furthermore, YKL-40
did not correlate with thrombocytopenia. An interaction between the platelets and the endothelium
have been suspected to have a role in the pathogenesis of capillary leakage in PUUV infection [54].
Taken together, YKL-40 does not seem to be a major factor in the development of vascular leakage in
PUUV infection.
The plasma YKL-40 level was associated with the severity of AKI, evaluated by the highest plasma
creatinine level. Previously, urine YKL-40 has mainly been studied in AKI. Increased urine YKL-40
has been found to predict AKI or death in hospitalized patients [55]. Marathon runners have been
found to develop AKI and have simultaneously elevated levels of plasma and urine YKL-40 [37,56].
On the other hand, donor urinary YKL-40 is associated with an improved kidney transplant recipient
outcome, suggesting that YKL-40 is produced in response to tubular injury as a factor promoting
kidney repair and predicting recovery from AKI [57]. Serum YKL-40, in turn, has been studied and
found to be elevated in patients with end-stage renal disease receiving RRT, as well as to serve as a
predictor for mortality when measured after RRT [58,59]. In the present study, high levels of plasma
YKL-40 predicted the development of more severe AKI in PUUV infection.
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In patients with diabetes, elevated plasma YKL-40 levels are associated with increasing amounts of
albuminuria [31,32]. In the present study, the plasma YKL-40 level was not associated with albuminuria,
hematuria, or glucosuria. Previously, in dipstick samples, both albuminuria and hematuria were found
to be associated with the severity of AKI in acute PUUV infection [27,28]. Furthermore, glucosuria was
also recently found to be a predictor for the severity of AKI [29]. In the present study, plasma YKL-40
was associated with the severity of AKI, but not directly with the urine dipstick findings. Previously,
high plasma resistin, as well as plasma suPAR levels, have been found to be associated with both AKI
and proteinuria [10,30]. The exact pathogenesis of AKI in PUUV infection has not been fully elucidated,
and the different biomarkers may reflect different pathogenetic mechanisms of AKI in PUUV infection.
Proteinuria in PUUV-infected patients probably reflects increased capillary leakage [27]. In the present
study, YKL-40 was not correlated with the markers of capillary leakage. Thus, the lack of correlation
of YKL-40 with proteinuria further strengthens the view that YKL-40 is not associated with vascular
leakage in PUUV infection.
In conclusion, plasma YKL-40 levels were found to be associated with the severity of Puumala
hantavirus infection in this study. It was connected with the overall severity of the disease, the level of
inflammation, as well as the severity of AKI.
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